Summary
Cetrorelix, (Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10)-LHRH (SB-75) is a new highly potent antagonist of LH-RH. In the model of DMBA-induced mammary carcinoma, this antagonist was very effective in reducing tumor mass. A rapid decrease in tumor weights to levels below 0.1 g total tumor mass was achieved with 300 μg/kg given sc. daily for 14 days. The weights of uteri and ovaries were reduced to about 40–50% of control values. In all treated rats the estrus cycle was interrupted and the animals remained in a state of anestrus. Microscopically, the effects of Cetrorelix on the tumors were characterized by a loss of mitotic activity, marked regression with apoptosis, an increase of stroma and differentiation towards a normal mammary architecture. On the basis of a dose-response curve, a dose of 100 μg/kg/d of Cetrorelix was determined as sufficient for a full antitumor response. Large DMBA-tumors with total tumor mass of about 6 g could also be treated very effectively with a dose of 100 μg/kg/d. To achieve a complete tumor regression, the treatment had to last 34 days. After the cessation of treatment with 100 μg/kg/d and regrowth of the tumors the animals were treated with the agonist Decapeptyl (Trp6-LHRH) using a dose of 50 μg/rat/d for 14 days. Again, the tumors responded well and regressed within 10 days. The treatment with an overlapping dose schedule of Cetrorelix and Decapeptyl showed a continuous antitumor response. A transient stimulation of tumor growth by the LH-RH agonist was not observed under these experimental conditions. In ovariectomized rats bearing DMBA-tumors, treatment with Cetrorelix and estradiol, produced no tumor growth inhibition as compared to estradiol control group, indicating that there is no estrogen nullifying effect of this antagonist on tumor cells in this model. On the basis of these results, Cetrorelix is a highly effective antitumor agent in this breast cancer model, which might also be useful under clinical conditions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV (1988a) New antagonists of LHRH. Int J Peptide Res 32:425–435
Bajusz S, Kovacs M, Gazdag M, Bokser L, Karashima T, Csernus VJ, Janaky T, Guoth J, Schally AV (1988b) Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci 85:1637–1641
Daniel PM, Prichard MLM (1963) The response of experimentally induced mammary tumors in rats to hypophysectomy and to pituitary stalk section. Br J Cancer 17:446–453
Debruyne FMJ, Weil EHJ, Del Moral F (1987) Clinical res8lts with the depot preparation of Zoladex in prostate cancer. In: Klijn JGM et al. (ed) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven Press, New York, p 255
DeSombre ER, Johnson ES, White WF (1976) Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res 36:3830–3833
Druckrey H, Steinhoff D, Nakayama M, Preussmann R, Anger K (1963) Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan. Dtsch Med Wochenschr 88:651
Fekete M, Bajusz S, Groot K, Csernus VJ, Schally AV (1989) Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology 124:946–955
Furr BJA, Milsted RAV (1982) Use of analogues of LH-RH for treatment of cancer. Endocr Management of Cancer 2:17–27
Gonzáles-Bárcena D, Vadillo-Buenfil M, Garcia-Porcel E, Mares G, Bajusz S, Comaru-Schally AM, Schally AV (1989) Inhibition of LH and FSH release in hypergonadotropic patients with new potent antagonists of LH-RH free of anaphylactoid reactions. The Endocrine Society, Meeting Seattle, Wash, Abstract No. 1712, p 450
Gonzáles-Bárcena D, Vadillo-Buenfil M, Guerra-Arguero E, Carenno J, Comaru-Schally AM, Schally AV (1990) Potent antagonistic analog of LH-RH (SB-75) inhibits LH, FSH and testosterone levels in human beings. The Endocrine Society, Meeting Atlanta, Ga, Abstract No. 1318, p 354
Hahn DW, McGuire JL, Vale WW, Rivier J (1985) Reproductive/endocrine and anaphylactoid properties of an LH-RH-antagonist, ORF-18260 (Ac-D-Nal1(2), 4FDPhe2, D-Trp3, D-Arg6)-GnRH. Life Sciences 37:505–514
Huggins C, Grand LC, Brillantes FP (1961) Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature 189:204–207
Jackson MI, Matthews MJ, Diver JMJ (1989) LH-RH analogues in the treatment of cancer. Cancer Treatment Rev 16:161–175
Jones TC, Mohr U, Hunt RD (1972) The genital system. In: Monographs on pathology of laboratory animals sponsered by the international life science institute. Springer, NY London
Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41:863–872
Mansfield MJ, Beardsworth DE, Loughlin JS, Crawford JD, Bode HH, Rivier J, Vale W, Kushner DC, Crigler JF, Crowley WF Jr (1983) Long-term treatment of central precocious puberty with a long--acting analogue of luteinizing hormone-releasing hormone. N Engl J Med 309:1286–1292
Redding TW, Schally AV (1983) Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone releasing hormone. Proc Natl Acad Sci 80:1459–1462
Redding TW, Schally AV (1989) Suppression of the pituitary-gonadal axis in nude mice by continuous administration of LH-RH agonists and antagonists. The Endocrine Society, 71st Annual Meeting, Seattle, Wash, No. 680, p 192
Russo J, Russo IH (1987) Biological and molecular basis of mammary carcinogenesis. Lab Invest 57:112–137
Schally AV, Kastin AJ, Arimura A (1971) Hypothalamic FSH and LH-regulating hormone: structure, physiology and clinical studies. Fertil Steril 22:703–721
Schally AV, Bajusz S, Redding TW, Zalatnai A, Comaru-Schally AM (1989) Analogs of LHRH. The present and the future. In: Vickery BH, Lunenfeld V (eds) GnRH analogs in cancer and in human reproduction, basic aspects. Kluwer Academic Publishers, Dordrecht/Boston/London, Vol 1:5–31
Schally AV, Redding TW (1987) Use of LH-RH analogs for the treatment of prostate cancer: combination therapy and direct effects. In: Klijn JGM et al. (ed) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven Press, New York, p 273
Schmidt F, Sundaram K, Thau RB, Bardin CW (1984) (Ac-D-Nal(2)1, 4FD-Phe2, D-Trp3, D-Arg6)-LH-RH, a potent antagonist of LH-RH, produces transient edema and behavioral changes in rats. Contraception 29:283–289
Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV (1989) Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci 86:1648–1651
Smith RD, Edgren RA (1982) Elevated blood preassure following LHRH antagonists in rats. Contraception 25:395–403
Szende B, Srkalovic G, Groot K, Lapis K, Schally AV (1990) Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J Natl Cancer Inst 82:513–517
Williams G, Kerle DJ, Roe SM, Yeo T, Bloom SR (1985) Results obtained in the treatment of prostate cancer patients with Zoladex. EORTC Genitourinary Group Monograph 2. Part A: Therapeutic principles in metastatic prostatic cancer. A.R. Liss, New York, pp 287–295
Zorn JR et al. (1990) Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients. Fert Ster 53:401–406
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reissmann, T., Hilgard, P., Harleman, J.H. et al. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. J Cancer Res Clin Oncol 118, 44–49 (1992). https://doi.org/10.1007/BF01192310
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01192310